Compare Freeport-McMoRan Inc (FCX) vs Medpace Holdings Inc (MEDP) Price & Performance

FCX trades at $71.13, down 1.02% today, with a bearish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong copper demand driven by AI infrastructure and data center growth provides positive momentum, while rising production costs present margin pressure. Analyst consensus remains bullish with a $73.27 price target, representing 3% upside from current levels.

FCX offers exposure to copper's structural demand growth but faces execution risks on expansion projects and cost inflation. The stock trades at premium valuations (P/E 34.87, P/S 3.97) requiring continued earnings delivery. Recent legal investigation and volatile commodity prices add near-term uncertainty, though institutional ownership and dividend payments provide stability for long-term investors.

Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.

The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.